David F. Cechetto
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
David F. Cechetto has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
Gary V. Allen
From Department of Anatomy and Cell Biology (S.N.W., N.A.B., G.C., D.F.C.), University of Western Ontario, London, Canada; Department of Anatomy & Neurobiology (G.V.A.), Faculty of Medicine, Sir Charles Tupper Medical Building, Dalhousie University, Halifax, Nova Scotia; Faculty of Medicine and Dentistry (V.C.H.), University of Western Ontario, London, Canada
1 shared publicationGuanliang Cheng
From Department of Anatomy and Cell Biology (S.N.W., N.A.B., G.C., D.F.C.), University of Western Ontario, London, Canada; Department of Anatomy & Neurobiology (G.V.A.), Faculty of Medicine, Sir Charles Tupper Medical Building, Dalhousie University, Halifax, Nova Scotia; Faculty of Medicine and Dentistry (V.C.H.), University of Western Ontario, London, Canada
1 shared publication- Joel Kevin Shoemaker
Western University
1 shared publication Nestor A. Bayona
From Department of Anatomy and Cell Biology (S.N.W., N.A.B., G.C., D.F.C.), University of Western Ontario, London, Canada; Department of Anatomy & Neurobiology (G.V.A.), Faculty of Medicine, Sir Charles Tupper Medical Building, Dalhousie University, Halifax, Nova Scotia; Faculty of Medicine and Dentistry (V.C.H.), University of Western Ontario, London, Canada
1 shared publicationShawn N Whitehead
1 shared publication- Shawn N. Whitehead
Institute for Biological Sciences, National Research Council of Canada, 1200 Montreal Rd, M54 Ottawa, Canada
1 shared publication
Latest Publications
- 1 September 2009
- Published by Elsevier in NeuroImage
- Vol. 47 (3) , 795-803
Functional neuroanatomy of autonomic regulation
- 1 September 2009
- Published by Elsevier in NeuroImage
- Vol. 47 (3) , 795-803
Functional neuroanatomy of autonomic regulation
- 1 May 2008
- Published by Taylor & Francis in Expert Review of Neurotherapeutics
- Vol. 8 (5) , 743-750
Vascular risk factors and Alzheimer’s disease
Vascular cognitive impairment risk factors include stroke, hypertension, diabetes and atherosclerosis. In the elderly, vascular risk factors occur in the presence of high levels of amyloid in the aging brain. Stroke alters the clinical expression of a given load of Alzheimer's disease (AD) pathology. Experimentally, large vessel infarcts or small striatal infarcts are larger in the presence of amyloid. Patients with minor cerebral infarcts and moderate AD lesions will develop the clinical manifestations of dementia. Moreover, there is also an association between other vascular risk factors and the clinical expression of cognitive decline and dementia. The risk of AD is increased in subjects with adult-onset diabetes mellitus, hypertension, atherosclerotic disease and atrial fibrillation. Experimentally, small striatal infarcts in the presence of high levels of amyloid in the brain exhibit a progression in infarct size over time with enhanced degree of cognitive impairment, AD-type pathology and neuroinflammation compared with striatal infarcts or high amyloid levels alone.
- 1 May 2008
- Published by Taylor & Francis in Expert Review of Neurotherapeutics
- Vol. 8 (5) , 743-750
Vascular risk factors and Alzheimer’s disease
Vascular cognitive impairment risk factors include stroke, hypertension, diabetes and atherosclerosis. In the elderly, vascular risk factors occur in the presence of high levels of amyloid in the aging brain. Stroke alters the clinical expression of a given load of Alzheimer's disease (AD) pathology. Experimentally, large vessel infarcts or small striatal infarcts are larger in the presence of amyloid. Patients with minor cerebral infarcts and moderate AD lesions will develop the clinical manifestations of dementia. Moreover, there is also an association between other vascular risk factors and the clinical expression of cognitive decline and dementia. The risk of AD is increased in subjects with adult-onset diabetes mellitus, hypertension, atherosclerotic disease and atrial fibrillation. Experimentally, small striatal infarcts in the presence of high levels of amyloid in the brain exhibit a progression in infarct size over time with enhanced degree of cognitive impairment, AD-type pathology and neuroinflammation compared with striatal infarcts or high amyloid levels alone.
- 1 February 2007
- Published by Wolters Kluwer Health in Stroke
- Vol. 38 (2) , 381-387
Effects of Triflusal and Aspirin in a Rat Model of Cerebral Ischemia
Background and Purpose— Neuroinflammation plays a critical role in the pathogenesis of cerebral ischemia. Triflusal, a selective cyclooxygenase-2, and its active metabolite 3-hydroxy-4-trifluoromethylbenzoic acid may inhibit apoptosis and inflammation after cerebral ischemia. An in vivo model of cerebral ischemia was used to investigate the effects of triflusal and aspirin treatment on infarct volume, and inflammation after cerebral ischemia in the rat. Methods— Male Wistar rats were subjected to a permanent right-sided middle cerebral artery occlusion. Rats received oral administration of either triflusal or aspirin. After 3 days after surgery, immunostaining was used to detect neuroinflammatory cells and molecules, and infarct volumes were measured. Results— Both triflusal and aspirin at a dose of 30 mg/kg but not 10 mg/kg significantly reduced infarct volume compared with vehicle treatment. Middle cerebral artery occlusion resulted in increased astrocyte and heat shock protein-27 (Hsp27) immunostaining in the ipsilateral cortex. Triflusal (30 mg/kg) or aspirin treatment (30 mg/kg) did not reduce the levels of GFAP or Hsp27 immunostaining. Triflusal (30 mg/kg) also significantly decreased the protein levels of IL-Iβ but not nuclear factor kappa B or tumor necrosis factor-α in the cortex ipsilateral to the middle cerebral artery occlusion. Conclusions— The results suggest that triflusal and aspirin appear to be equally neuroprotective against middle cerebral artery occlusion-induced cerebral ischemia. Therefore, strong rationale exists to continue the neuroprotective examination of triflusal in brain injury.
- 1 February 2007
- Published by Wolters Kluwer Health in Stroke
- Vol. 38 (2) , 381-387
Effects of Triflusal and Aspirin in a Rat Model of Cerebral Ischemia
Background and Purpose— Neuroinflammation plays a critical role in the pathogenesis of cerebral ischemia. Triflusal, a selective cyclooxygenase-2, and its active metabolite 3-hydroxy-4-trifluoromethylbenzoic acid may inhibit apoptosis and inflammation after cerebral ischemia. An in vivo model of cerebral ischemia was used to investigate the effects of triflusal and aspirin treatment on infarct volume, and inflammation after cerebral ischemia in the rat. Methods— Male Wistar rats were subjected to a permanent right-sided middle cerebral artery occlusion. Rats received oral administration of either triflusal or aspirin. After 3 days after surgery, immunostaining was used to detect neuroinflammatory cells and molecules, and infarct volumes were measured. Results— Both triflusal and aspirin at a dose of 30 mg/kg but not 10 mg/kg significantly reduced infarct volume compared with vehicle treatment. Middle cerebral artery occlusion resulted in increased astrocyte and heat shock protein-27 (Hsp27) immunostaining in the ipsilateral cortex. Triflusal (30 mg/kg) or aspirin treatment (30 mg/kg) did not reduce the levels of GFAP or Hsp27 immunostaining. Triflusal (30 mg/kg) also significantly decreased the protein levels of IL-Iβ but not nuclear factor kappa B or tumor necrosis factor-α in the cortex ipsilateral to the middle cerebral artery occlusion. Conclusions— The results suggest that triflusal and aspirin appear to be equally neuroprotective against middle cerebral artery occlusion-induced cerebral ischemia. Therefore, strong rationale exists to continue the neuroprotective examination of triflusal in brain injury.